Clinical Trial

SIL as Maintenance Therapy in Multiple Myeloma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
Trial Details
NCT Number NCT06744894
Lead Sponsor Navy General Hospital, Beijing
Conditions Multiple Myeloma
Enrollment 50 participants
Start Date 2025-01-01
Primary Completion 2028-01-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20